Einar Bjarki Gunnarsson

Einar Bjarki Gunnarsson

Auto-generated profile, based on publicly available information

Einar Bjarki Gunnarsson

Department of Industrial and Systems Engineering, University of Minnesota, Twin Cities, MN 55455, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Journal of Theoretical Biology
Verified
Journal Article
Closed access
EGEinar Bjarki Gunnarsson
Einar Bjarki Gunnarsson
SDSubhajyoti De
Subhajyoti De
KLKevin Leder
Kevin Leder
JFJasmine Foo
Jasmine Foo

1 December 2021 in Theoretical Population Biology
Verified
Journal Article
Closed access
EGEinar Bjarki Gunnarsson
Einar Bjarki Gunnarsson
KLKevin Leder
Kevin Leder
JFJasmine Foo
Jasmine Foo

11 January 2025 in Stochastic Processes and their Applications
Verified
Journal Article
Closed access
EGEinar Bjarki Gunnarsson
Einar Bjarki Gunnarsson
KLKevin Leder
Kevin Leder
XZXuanming Zhang
Xuanming Zhang

12 June 2023 in Communications on Applied Mathematics and Computation
Verified
Journal Article
Closed access
PDF file
JFJasmine Foo
Jasmine Foo
EGEinar Bjarki Gunnarsson
Einar Bjarki Gunnarsson
KLKevin Leder
Kevin Leder
DSDavid Sivakoff
David Sivakoff

21 January 2020 in arXiv
Verified
Preprint
Open access
PDF file
EGEinar Bjarki Gunnarsson
Einar Bjarki Gunnarsson
SDSubhajyoti De
Subhajyoti De
KLKevin Leder
Kevin Leder
JFJasmine Foo
Jasmine Foo
The emergence of acquired drug resistance in cancer represents a major barrier to treatment success. While research has traditionally focused on genetic sources of resistance, recent findings suggest that cancer cells can acquire transient resistant phenotypes via epigenetic modifications and other non-genetic mechanisms. Although these resistant phenotypes are eventually relinquished by individual cells, they can temporarily 'save' the tumor from extinction and enable the emergence of more permanent resistance mechanisms. These observations have generated interest in the potential of epigenetic therapies for long-term tumor control or eradication. In this work, we develop a mathematical model to study how phenotypic switching at the single-cell level affects resistance evolution in cancer. We highlight unique features of non-genetic resistance, probe the evolutionary consequences of epigenetic drugs and explore potential therapeutic strategies. We find that even short-term epigenetic modifications and stochastic fluctuations in gene expression can drive long-term drug resistance in the absence of any bona fide resistance mechanisms. We also find that an epigenetic drug that slightly perturbs the average retention of the resistant phenotype can turn guaranteed treatment failure into guaranteed success. Lastly, we find that combining an epigenetic drug with an anti-cancer agent can significantly outperform monotherapy, and that treatment outcome is heavily affected by drug sequencing.

31 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SKSeungil Kim
Seungil Kim
EGEinar Bjarki Gunnarsson
Einar Bjarki Gunnarsson
MDMichael E. Doche
Michael E. Doche
YZYuyuan Zhou
Yuyuan Zhou
YHYu-Kai Huang
Yu-Kai Huang
Shannon MumenthalerShannon Mumenthaler
Shannon Mumenthaler
SUMMARY: Patient-derived tumor organoids provide a physiologically relevant 3D disease model for preclinical drug discovery, surpassing the limitations of conventional 2D cell lines. To better capture the dynamic nature of organoid drug responses, we developed a new systematic evaluation method called SCOPE (Systematic Classification of Organoids for Phenotypic Evaluation), harnessing phenotypic assessments from multi-timepoint 3D imaging data. By integrating artificial intelligence (AI)-based image analysis of organoid viability with tracking and mathematical modeling of organoid growth over time, we captured temporal-and dose-dependent dynamics of phenotypic changes, culminating in two novel metrics: a combined growth and viability ( GV ) score as well as a cytostatic-cytotoxic transition range (CCTR) that separates drug effects on organoid growth and viability. Our approach supports classification of specific drug responses into four distinct phenotypic groups: (1) cytotoxic, (2) cytostatic plus cytotoxic, (3) late cytotoxic, and (4) cytostatic. This novel drug evaluation system can identify previously unknown drug effects or new therapeutic use cases for existing drugs, facilitating the design of alternative therapeutic options to overcome efficacy or drug resistance challenges and improving the clinical applicability of organoid-based drug discovery results.